Cargando…

An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response

BACKGROUND: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers; the majority of EOC is the serous histotype and diagnosed at advanced stage. IL6 is the cytokine that has been found most frequently associated with carcinogenesis and progression of serous EOCs. IL6 is a gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinciroli, Patrizia, Alberti, Chiara, Sensi, Marialuisa, Canevari, Silvana, Tomassetti, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728068/
https://www.ncbi.nlm.nih.gov/pubmed/23889749
http://dx.doi.org/10.1186/1471-2164-14-508
_version_ 1782278799453323264
author Pinciroli, Patrizia
Alberti, Chiara
Sensi, Marialuisa
Canevari, Silvana
Tomassetti, Antonella
author_facet Pinciroli, Patrizia
Alberti, Chiara
Sensi, Marialuisa
Canevari, Silvana
Tomassetti, Antonella
author_sort Pinciroli, Patrizia
collection PubMed
description BACKGROUND: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers; the majority of EOC is the serous histotype and diagnosed at advanced stage. IL6 is the cytokine that has been found most frequently associated with carcinogenesis and progression of serous EOCs. IL6 is a growth-promoting and anti-apoptotic factor, and high plasma levels of IL6 in advanced stage EOCs correlate with poor prognosis. The objective of the present study was to identify IL6 co-regulated genes and gene network/s in EOCs. RESULTS: We applied bioinformatics tools on 7 publicly available data sets containing the gene expression profiles of 1262 EOC samples. By Pearson's correlation analysis we identified, in EOCs, an IL6-correlated gene signature containing 40 genes mainly associated with proliferation. 33 of 40 genes were also significantly correlated in low malignant potential (LMP) EOCs, while 7 genes, named C5AR1, FPR1, G0S2, IL8, KLF2, MMP19, and THBD were IL6-correlated only in advanced stage EOCs. Among the 40-gene signature EGFR ligand HBEGF, genes of the EGR family members and genes encoding for negative feedback regulators of growth factor signaling were included. The results obtained by Gene Set Enrichment and Ingenuity Pathway Analyses enabled the identification, respectively, of gene sets associated with ‘early growth factor response’ for the 40-gene signature, and a biological network related to ‘thrombosis and cardiovascular disease’ for the 7-gene signature. In agreement with these results, selected genes from the identified signatures were validated in vitro by real time RT-PCR in serous EOC cell lines upon stimulation with EGF. CONCLUSIONS: Serous EOCs, independently of their aggressiveness, co-regulate IL6 expression together with that of genes associated to growth factor signaling, arguing for the hypothesis that common mechanism/s driven by EGFR ligands characterize both advanced-stage and LMP EOCs. Only advanced-stage EOCs appeared to be characterized by a scenario that involves genes which are so far associated with thrombosis and cardiovascular disease, thus suggesting that this pathway is implicated in the growth and/or spread of more aggressive tumors. We have discovered novel activated signaling pathways that drive the expression of IL6 and of co-regulated genes and are possibly involved in the pathobiology of EOCs.
format Online
Article
Text
id pubmed-3728068
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37280682013-07-31 An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response Pinciroli, Patrizia Alberti, Chiara Sensi, Marialuisa Canevari, Silvana Tomassetti, Antonella BMC Genomics Research Article BACKGROUND: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers; the majority of EOC is the serous histotype and diagnosed at advanced stage. IL6 is the cytokine that has been found most frequently associated with carcinogenesis and progression of serous EOCs. IL6 is a growth-promoting and anti-apoptotic factor, and high plasma levels of IL6 in advanced stage EOCs correlate with poor prognosis. The objective of the present study was to identify IL6 co-regulated genes and gene network/s in EOCs. RESULTS: We applied bioinformatics tools on 7 publicly available data sets containing the gene expression profiles of 1262 EOC samples. By Pearson's correlation analysis we identified, in EOCs, an IL6-correlated gene signature containing 40 genes mainly associated with proliferation. 33 of 40 genes were also significantly correlated in low malignant potential (LMP) EOCs, while 7 genes, named C5AR1, FPR1, G0S2, IL8, KLF2, MMP19, and THBD were IL6-correlated only in advanced stage EOCs. Among the 40-gene signature EGFR ligand HBEGF, genes of the EGR family members and genes encoding for negative feedback regulators of growth factor signaling were included. The results obtained by Gene Set Enrichment and Ingenuity Pathway Analyses enabled the identification, respectively, of gene sets associated with ‘early growth factor response’ for the 40-gene signature, and a biological network related to ‘thrombosis and cardiovascular disease’ for the 7-gene signature. In agreement with these results, selected genes from the identified signatures were validated in vitro by real time RT-PCR in serous EOC cell lines upon stimulation with EGF. CONCLUSIONS: Serous EOCs, independently of their aggressiveness, co-regulate IL6 expression together with that of genes associated to growth factor signaling, arguing for the hypothesis that common mechanism/s driven by EGFR ligands characterize both advanced-stage and LMP EOCs. Only advanced-stage EOCs appeared to be characterized by a scenario that involves genes which are so far associated with thrombosis and cardiovascular disease, thus suggesting that this pathway is implicated in the growth and/or spread of more aggressive tumors. We have discovered novel activated signaling pathways that drive the expression of IL6 and of co-regulated genes and are possibly involved in the pathobiology of EOCs. BioMed Central 2013-07-26 /pmc/articles/PMC3728068/ /pubmed/23889749 http://dx.doi.org/10.1186/1471-2164-14-508 Text en Copyright © 2013 Pinciroli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pinciroli, Patrizia
Alberti, Chiara
Sensi, Marialuisa
Canevari, Silvana
Tomassetti, Antonella
An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title_full An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title_fullStr An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title_full_unstemmed An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title_short An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
title_sort il6-correlated signature in serous epithelial ovarian cancer associates with growth factor response
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728068/
https://www.ncbi.nlm.nih.gov/pubmed/23889749
http://dx.doi.org/10.1186/1471-2164-14-508
work_keys_str_mv AT pincirolipatrizia anil6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT albertichiara anil6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT sensimarialuisa anil6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT canevarisilvana anil6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT tomassettiantonella anil6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT pincirolipatrizia il6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT albertichiara il6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT sensimarialuisa il6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT canevarisilvana il6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse
AT tomassettiantonella il6correlatedsignatureinserousepithelialovariancancerassociateswithgrowthfactorresponse